On December 2, 2024, Bruce Cozadd, Chairman & CEO of Jazz Pharmaceuticals PLC, sold 2,000 shares of the company, as reported in a SEC Filing. Following this transaction, the insider now owns 427,025 shares of the company.
Jazz Pharmaceuticals PLC (JAZZ, Financial) is a global biopharmaceutical company focused on developing and commercializing pharmaceutical products that address unmet medical needs. The company is known for its expertise in neuroscience, oncology, and sleep medicine.
The insider transaction history for Jazz Pharmaceuticals PLC indicates that there have been 1 insider buy and 8 insider sells over the past year. Over the same period, Bruce Cozadd has sold a total of 3,000 shares and has not purchased any shares.
On the day of the recent sale, shares of Jazz Pharmaceuticals PLC were trading at $121.17, giving the stock a market cap of $7.463 billion. The company's price-earnings ratio stands at 17.39, which is lower than the industry median of 26.55 and also lower than the company’s historical median price-earnings ratio.
With a trading price of $121.17 and a GF Value of $150.36, Jazz Pharmaceuticals PLC has a price-to-GF-Value ratio of 0.81, indicating that the stock is modestly undervalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples, a GuruFocus adjustment factor, and future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
